

# INDEX

Note: Page numbers followed by “*f*” indicate figures, and “*t*” indicate tables.

## A

- Antibody-dependent enhancement of infectivity (ADEI), 270–271
- Antiviral selection, CoV
  - enzymatic activities, 273
  - inhibitors, vacuolar acidification, 273–274
  - p38 MAPK, 274

## C

- Cap-dependent translation, 170–171
- Cellular proteins, CoV replication
  - BCoV, 150
  - DDX5 and DDX1, 151
  - hnRNP A1, 149–150
  - PABP, 150
  - TGEV, 149–150
- Circulating virulent-avirulent FCoV hypothesis, 203–204
- cis*-acting RNA elements, CoV
  - cellular proteins, role of
    - BCoV, 150
    - DDX5 and DDX1, 151
    - hnRNP A1, 149–150
    - PABP, 150
    - TGEV, 149–150
  - Coronaviridae* classification, 128
  - DI RNAs
    - definition, 131–132
    - identification and characterization, 132
    - leader switching, 132
  - genome replication and transcription
    - 3′-5′ exoribonuclease, 129–130
    - ORF, 131
    - RdRp, 129–130
    - Sg minus-strand RNAs, 130–131
    - transcription-regulating sequences (TRSs), 130–131
  - nsp, 128–129
  - ORF1a and ORF1b, 128–129
  - RNA elements and genome packaging, 148–149

- subgenomic messenger RNAs (sg mRNAs), 128–129
- 3′-terminal
  - functional roles, 145–148
  - structural features, 142–145
- 5′-terminal
  - functional roles, 136–141
  - structural features, 133–136
- zoonotic coronaviruses, 128
- Coronavirus (CoV)
  - eIF2 $\alpha$  phosphorylation activation, 182–183
  - ER stress and unfolded protein response, 180–181
  - genome organization and gene expression strategy
    - discontinuous extension, 170
    - eIF4F and the 43S preinitiation complex, 169–170
    - ORFs, 169
    - subgenomic minus-strand RNAs, 170
    - transcription regulatory sequences (TRS), 169
  - HCoV
    - 229E-infected cells, 170–171, 184
    - ORF, 174–175
    - SARS-CoV and MERS-CoV, 168
  - m<sup>6</sup>A-modification, 184
  - MERS-CoV, 168
  - MHV-infected cells, 184–185
  - mRNA translation
    - cap-dependent translation, 170–171
    - IRES-mediated translation, 175–176
    - leaky scanning translation mechanism, internal ORFs, 174–175
    - N protein-mediated enhancement, 177–178
    - poly(A) tail length changes, 172
    - ribosomal frameshift, 172–173
    - ribosomal shunting mechanism, 174
    - structural features, 184
    - upstream ORFs (uORF), 176

Coronavirus (CoV) (*Continued*)

- viral enzymes, 171–172
- viral UTRs, 177
- PERK activation, 182–183
- PKR activation, 182–183
- protein suppressors, translation
  - 7a protein, 180
  - eIF3f, 180
  - elongation factor 1 alpha (eEF1 $\alpha$ ), 180
  - MERS-CoV nsp1, 179
  - SARS-CoV nsp1, 179
  - 40S ribosomal subunits, 178–179
- SARS-CoV, 168
- stress granules and processing bodies, 181–182
- structural proteins, 168–169
- translation mechanism, animal cells
  - cap-dependent translation initiation, 167–168
  - eukaryotic cells, 166–167
  - eukaryotic initiation factors (eIFs), 167
  - IRES, 167–168
  - viral gene expression, 183–184
- CoV S protein. *See* Spike protein (S) and tropism changes, CoV
- Cross-species transmission, 31

**D**

- Defective interfering RNAs (DI RNAs)
  - definition, 131–132
  - identification and characterization, 132
  - leader switching, 132
- Dendritic cells (DCs)
  - cytokines and chemokines, 273
  - immune cells, SARS-CoV and MERS-CoV, 271, 272*t*
  - MERS-CoV interaction, 272
  - SARS-CoV, 272–273
  - virus replication, 271–272

**E**

- Envelope protein
  - SARS-CoV, 10
  - structural features, 10–11
  - VLP, 9–10
- Eosinophilia induction, 270–271
- Epithelial cells, 271

**F**

- Feline coronaviruses (FCoVs)
  - accessory genes and proteins
    - ORF 3a, 196
    - ORF7a, 196–197
    - ORF 3b, 196
    - ORF7b, 196–197
    - ORF 3c, 196
    - S and E genes, 195–196
    - sgRNA3, 196
    - TGEV, 195–196
  - discriminatory mutations, 210
- FECV
  - seropositivity rates, 199
  - symptomless persistent infections, 199–200
  - transmission, 200
- FIPV
  - characteristic lesions, 200–201
  - clinical forms, 201–202
  - immunosuppression, 202
  - incidence of, 203
  - incubation time, 202
  - origin of, 203–204
- molecular pathogenesis, FECV *vs.* FIPV
  - 7a gene, 204
  - 7b gene, 204–205
  - 3c gene, 204
  - furin cleavage site, 206
  - heptad repeat 1 (HR1) region, 205–206
  - mutations, 205
- reverse genetics
  - bacterial artificial chromosome (BAC), 207–208
  - cDNA, 208–209
  - FCoV Black sequence, 209–210
  - recombinant viruses, 207
  - targeted RNA recombination, 206–207
- role of accessory proteins, 211
- serotypes and cellular receptor usage
  - feline aminopeptidase N (fAPN), 198–199
  - serotype I, 197–198
  - serotype II, 198–199
- S gene mutations, 210
- taxonomy and genome organization, 194–195, 195*f*

Feline enteric coronavirus (FECV)  
*vs.* FIPV  
 7a gene, 204  
 7b gene, 204–205  
 3c gene, 204  
 furin cleavage site, 206  
 heptad repeat 1 (HR1) region,  
 205–206  
 mutations, 205  
 seropositivity rates, 199  
 symptomless persistent infections,  
 199–200  
 transmission, 200

Feline infectious peritonitis (FIP), 204–206.  
*See also* Feline infectious peritonitis  
 virus (FIPV)

Feline infectious peritonitis virus (FIPV)  
 characteristic lesions, 200–201  
 clinical forms, 201–202  
*vs.* FECV  
 7a gene, 204  
 7b gene, 204–205  
 3c gene, 204  
 furin cleavage site, 206  
 heptad repeat 1 (HR1) region, 205–206  
 mutations, 205  
 immunosuppression, 202  
 incidence of, 203  
 incubation time, 202  
 origin of, 203–204

## G

Genome replication and transcription  
 3'-5' exoribonuclease, 129–130  
 ORF, 131  
 RdRp, 129–130  
 Sg minus-strand RNAs, 130–131  
 transcription-regulating sequences  
 (TRSs), 130–131  
 Genomic packaging signal (PS)  
 conservation and lineage, 148–149  
 discovery, 148–149  
 role of, 149  
 TGEV, 149

## H

Host gene expression, 178–179  
 Host translational shutoff, 181–182

Human CoV (HCoV)  
 229E-infected cells, 170–171, 184  
 IFN response  
 human MxA, 227–228  
 IFITMs, 227–228  
 ISG, 228  
 2'-5' oligoadenylate synthetase (OAS),  
 227–228  
 ORF, 174–175  
 SARS-CoV and MERS-CoV, 168

## I

IFN-gamma, 223  
 IFN-induced transmembrane (IFITMs),  
 227–228  
 IFN-lambda 1–4, 223  
 Inactivated whole virus, 256  
 Innate immunity modulators, 261–263, 261*f*  
 Interferon (IFN) response  
 antiviral action, human CoV  
 human MxA, 227–228  
 IFITMs, 227–228  
 IFN-stimulated genes (ISG), 228  
 2'-5' oligoadenylate synthetase (OAS),  
 227–228  
 CoV genome  
 genome organization, 220–221, 221*f*  
 life cycle, 221–222  
 RTC, 221–222  
 sgRNA, 221–222  
 induction, inhibition of  
 dsRNA, 228–229  
 IRF3, 229–231  
 mechanisms and factors, 229–231,  
 230–231*t*  
 MHV-A59, 229  
 ORF4a and ORF4b protein, 231–232  
 pDCs, 229  
 resistance, 233–234, 233*t*  
 signaling, inhibition of, 232–233, 232*t*  
 type I  
 induction of, 224–225  
 stimulated gene expression, 225–226  
 types and signaling pathways, 222–223  
 Internal mutation hypothesis, 203–204  
 Internal ribosome entry site  
 (IRES)-mediated translation,  
 175–176

**L**

- Leaky scanning translation mechanism,
  - internal ORFs, 174–175
- Live-attenuated vaccines
  - engineer attenuated CoVs, 258
  - IFN sensitivity, 259–261
  - innate immunity modulators, 261–263, 261*f*
  - MERS-CoV genes, 267–269
  - SARS-CoV genes, 263–267
  - virulence of, 258–259

**M**

- Macrophages (MØ)
  - cytokines and chemokines, 273
  - immune cells, SARS-CoV and MERS-CoV, 271, 272*t*
  - MERS-CoV interaction, 272
  - SARS-CoV, 272–273
  - virus replication, 271–272
- Membrane protein
  - appearance and characteristics, 7–8, 7*f*
  - endodomains, 6
  - MLONG-RNP interactions, 6
  - virus-like particles (VLP) assembly, 6–8
- Middle East respiratory syndrome (MERS) CoV
  - animal model, 253
  - antigenic complexity, 250–251
  - antiviral interferon response
    - (see Interferon (IFN) response)
  - cryo-EM reconstruction, 2–4, 3*f*
  - DCs, interaction, 272–273
  - DPP4, 252
    - as drug target, 89–90
  - envelope protein, 10
  - E protein, 10–11
  - ExoN, 102–103
  - HCoV, 168
  - hDPP4, 253–254
  - HR1 mutation, 46–47
  - immune cells, 271, 272*t*
  - interactions, 151
  - live-attenuated vaccines, 263–269
  - M protein, 9–10
  - NiRAN, 79
  - N protein, 8

- nsp1, 179
- nsp7, 67–68, 68*f*
- nsp8, 68–70
- nsp9, 70–71
- nsp10, 71–72
- nsp12, 76–77
- nsp13, 81–82, 82*f*
- nsp14, 103–104
- nsp15, 106–109
- nsp16, 97–98, 100–101
- origin, 30–31
- p38 MAPK, 274
- protein receptor preference, 39
- proteolytic cleavage sites, 45–46
- RBM, 37–38
- S<sub>1</sub> CTR changes, 43–44
- SL3, 133–135
- spike protein, 12
- survival time, 5
- 5′-terminal genome, 136–137
- transmission, 252
- Molecular pathogenesis, FIP, 204–206
- mRNA translation, CoV
  - cap-dependent translation, 170–171
  - IRES-mediated translation, 175–176
  - leaky scanning translation mechanism,
    - internal ORFs, 174–175
  - N protein-mediated enhancement, 177–178
  - poly(A) tail length changes, 172
  - ribosomal frameshift, 172–173
  - ribosomal shunting mechanism, 174
  - structural features, 184
  - upstream ORFs (uORF), 176
  - viral enzymes, 171–172
  - viral UTRs, 177

**N**

- Nidovirus RdRp-associated
  - nucleotidyltransferase (NiRAN) domain, 78–80
- Nonstructural protein (nsp) 7, 67–68, 68*f*
- Nonstructural protein (nsp) 9, 70–71
- Nonstructural protein (nsp)10, 71–72
- Nonstructural protein (nsp) 10–13–14–16
  - cap structure, 91–92
  - interferon-stimulated genes (ISGs), 90–91
  - 7-methylguanosine (<sup>m7</sup>G), 90

- mRNA, 90–91
- nsp14 N7-methyl transferase, 94–97, 95–96*f*
- nsp16 2'-*O*-methyl transferase, 97–101, 99–100*f*
- nsp13 RNA 5' triphosphatase, 92–93
- RNA guanylyl transferase (GTase), 93
- Nonstructural protein (nsp)12
- characterization, 72–73
- inhibitors, 77–78
- initiation mechanism, 74–77, 75*f*
- NiRAN domain, 78–80
- RdRp domain, 73–74
- virus-encoded RdRp, 72–73
- Nonstructural protein (nsp)13
- drug target, 89–90
- functional characterization, nidovirus
- helicase, 86–89
- HEL1, 81–83, 82*f*
- helicase-associated ZBD, 83–84
- nidovirus helicase structural biology, 84–86
- superfamilies (SFs), 80–81
- Nonstructural protein (nsp) 15
- conserved domain, 108
- hexameric form, 109
- hexamerization, 109
- His residues, 110–111
- interrelated by topological permutation, 109
- Mn<sup>2+</sup> ions, 107–108
- nidovirus endoU domains, 106–107, 107*f*
- recombinant forms, 107–108
- RNase A, 110
- XendoU, *Xenopus laevis*, 106–107, 107*f*
- Nonstructural protein (nsp) 8 and nsp7–nsp8 complexes, 68–70
- Nonstructural protein (nsp) 14 ExoN
- DEDD exonucleases, 102
- genome size and ExoN conservation, 102–103
- metal ion-coordinating residues, 105–106
- Mg<sup>2+</sup> or Mn<sup>2+</sup> ions, 104
- N7-MTase domain, 103–104
- nsp10–nsp14 complexes, 104–105
- SARS-CoV, 102–103
- zinc finger, 105
- N protein-mediated enhancement, 177–178
- Nucleoprotein
- conservation of, 9, 9*f*
- C-terminal domain (CTD), 8–9
- kinases, 8
- N-terminal domain, 8–9
- P**
- Pathogen recognition receptors (PRRs), 224–225
- Protein kinase, RNA activated (PKR), 224–225
- Protein suppressors, CoV
- 7a protein, 180
- eIF3f, 180
- elongation factor 1 alpha (eEF1α), 180
- MERS-CoV nsp1, 179
- SARS-CoV nsp1, 179
- 40S ribosomal subunits, 178–179
- Proteolytic cleavage and conformational changes
- prefusion conformation, 40–41
- receptor mediated endocytosis, 39–40
- virus-cell fusion, 39–40
- R**
- Receptor-binding domain (RBD), 37–38
- Receptor interactions, S<sub>1</sub> subunit
- C-terminal region (CTR) changes, 43–44
- N-terminal region (NTR) changes, 42–43
- Replication and transcription complex (RTC)
- IFN response, 221–222
- RNA synthesis and processing, 64, 112
- Reverse genetics, FCoV
- bacterial artificial chromosome (BAC), 207–208
- cDNA, 208–209
- FCoV Black sequence, 209–210
- recombinant viruses, 207
- targeted RNA recombination, 206–207
- Ribosomal frameshift, 172–173
- Ribosomal shunting mechanism, 174
- RIG-I-like receptors (RLRs), 225
- RNA-dependent RNA polymerase (RdRp)
- genome replication and transcription, 129–130
- inhibitors, 77–78

- RNA-dependent RNA polymerase (RdRp)  
(*Continued*)  
initiation mechanism, 74–77, 75f  
recombinant expression, 74
- RNA elements, CoV. *See cis-acting RNA elements, CoV*
- RNA synthesis and processing, CoVs  
accessory proteins, 64–65  
antibody availability, 67  
cell culture models, 66–67  
3C-like protease (3CL<sup>Pro</sup>), 61–63  
core replicase domains, 61  
error rate and genomic  
plasticity, 113  
genome organization and expression  
strategy, 61–63, 62f  
nidoviruses, 61  
nsp 7, 67–68, 68f  
nsp 9, 70–71  
nsp 10, 71–72  
nsp 10–13–14–16  
cap structure, 91–92  
interferon-stimulated genes (ISGs),  
90–91  
7-methylguanosine (<sup>m7</sup>G), 90  
mRNA, 90–91  
nsp14 N7-methyl transferase, 94–97,  
95–96f  
nsp16 2'-O-methyl transferase,  
97–101, 99–100f  
nsp13 RNA 5' triphosphatase,  
92–93  
RNA guanylyl transferase (GTase), 93  
nsp12  
characterization, 72–73  
inhibitors, 77–78  
initiation mechanism, 74–77, 75f  
NiRAN domain, 78–80  
RdRp domain, 73–74  
virus-encoded RdRp, 72–73  
nsp13  
drug target, 89–90  
functional characterization, nidovirus  
helicase, 86–89  
HEL1, 81–83, 82f  
helicase-associated ZBD, 83–84  
nidovirus helicase structural biology,  
84–86  
superfamilies (SFs), 80–81
- nsp15  
conserved domain, 108  
hexameric form, 109  
hexamerization, 109  
His residues, 110–111  
interrelated by topological  
permutation, 109  
Mn<sup>2+</sup> ions, 107–108  
nidovirus endoU domains, 106–107,  
107f  
recombinant forms, 107–108  
RNase A, 110  
XendoU, *Xenopus laevis*, 106–107, 107f
- nsp8 and nsp7–nsp8 complexes, 68–70
- nsp 14 ExoN  
DEDD exonucleases, 102  
genome size and ExoN conservation,  
102–103  
metal ion-coordinating residues,  
105–106  
Mg<sup>2+</sup> or Mn<sup>2+</sup> ions, 104  
N7-MTase domain, 103–104  
nsp10–nsp14 complexes, 104–105  
SARS-CoV, 102–103  
zinc finger, 105
- nsp interactome, 65–66  
open reading frames (ORFs), 61–63  
papain-like proteases (PL<sup>Pro</sup>), 61–63  
RTC, 64, 112  
subgenomic (sg) mRNAs, 64–65  
traditional genetic methods, 112–113  
transcriptionregulatory sequences  
(TRSs), 65  
transmission, 60–61  
ubiquitin, 61–63
- S**
- Severe acute respiratory syndrome  
(SARS) CoV  
eEF $\alpha$ , 180  
ER stress, 181  
HCoV, 168  
host mRNA decay, 184  
IRES-driven translation, 179  
nsp1, 179  
stimulatory structure, 173
- Spike protein  
HR1 and HR2, 12–13  
MERS-CoV, 12

- S1 and S2 regions, 11–12
  - SARS-CoV, 12
  - Spike protein (S) and tropism changes, CoV
    - cross-species transmission, 31
    - MERS-CoV, 30–31
    - mutations
      - FIPV, 41–42
      - S<sub>2</sub> mutations, altered tropism, 45–47
      - S<sub>1</sub> receptor interactions, 42–44
    - origin, 30
    - proteolytic cleavage and conformational changes
      - prefusion conformation, 40–41
      - receptor mediated endocytosis, 39–40
      - virus-cell fusion, 39–40
    - SARS-CoV, 30–31
    - spike-receptor interactions
      - protein receptor preference, 39
      - RBD, 37–38
    - structural proteins, 30
    - structure of
      - S<sub>1</sub> subunit, 32–34, 33–36*f*
      - S<sub>2</sub> subunit, 33–34*f*, 34–37
      - trimers, 31–32
  - Spike-receptor interactions
    - protein receptor preference, 39
    - RBD, 37–38
  - S<sub>1</sub> subunit
    - RBD, 37–38
    - receptor interactions
      - C-terminal region (CTR) changes, 43–44
      - N-terminal region (NTR) changes, 42–43
    - structure of, 32–34, 33–36*f*
  - S<sub>2</sub> subunit
    - mutations
      - altered tropism, 46–47
      - proteolytic cleavage sites, changes in, 45–46
    - structure of, 33–34*f*, 34–37
  - Subunit vaccines, 254–256
  - Supramolecular architecture
    - evolution, structural proteins
      - CTD, 15
      - M and N, 13–14
      - nidovirus structural proteins, 14–15, 14*f*
      - pleomorphic nidovirus, 15–16
      - VLP, 14–15
    - packaged host-encoded protein, 1–2
    - S–E–M–N genes, 2–4
    - structure and organization, 2–4, 3*f*
    - viral genome, 1–2
    - viral proteins
      - envelope protein, 9–11
      - membrane protein, 5–8
      - nucleoprotein, 8–9
      - spike protein, 11–13
    - virion structure and durability, 4–5
- T**
- 3'-terminal *cis*-acting RNA elements
    - functional roles
      - BSL and pseudoknot, 146–147
      - hypervariable region (HVR), 147
      - 3'-terminal poly(A) tail, 147–148
    - structural features
      - bulged stem-loop (BSL), 143
      - hairpin-type pseudoknot (PK) structure, 143–144
      - hypervariable region (HVR), 145
      - MHV genome, 143–145
      - TGEV and FCoV, 141–142
  - 5'-terminal *cis*-acting RNA elements
    - functional roles
      - DI RNA replication, 136–137
      - SARS-CoV, 136–137
      - stem-loop 3, 138–139
      - stem-loop 4, 139–140
      - stem-loop 5, 140–141
      - stem-loops 1 and 2, 137–138
    - structural features
      - MHV, 133, 134*f*
      - RNA structure, 135–136
      - SARS-CoV, 133–135
      - selective 2'-hydroxyl acylation and primer extension (SHAPE) method, 135–136
      - stem-loops (SLs), 133
  - Translation mechanism, CoV
    - cap-dependent translation initiation, 167–168
    - eukaryotic cells, 166–167

- Translation mechanism, CoV (*Continued*)  
 eukaryotic initiation factors  
 (eIFs), 167  
 internal ribosome entry site (IRES),  
 167–168
- Transmissible gastroenteritis virus (TGEV),  
 195–196
- Tropism changes, S protein mutations  
 canine CoVs (CCoVs), 41–42  
 feline CoV (FECV), 41–42  
 FIPV, 41–42  
 S<sub>2</sub> mutations  
 altered tropism, 46–47  
 proteolytic cleavage sites, changes in,  
 45–46  
 S<sub>1</sub> receptor interactions  
 C-terminal region (CTR) changes,  
 43–44  
 N-terminal region (NTR) changes,  
 42–43
- Type I IFN system  
 induction of, 224–225  
 stimulated gene expression, 225–226  
 types and signaling pathways  
 IFN-gamma, 223  
 IFN-lambda 1–4, 223  
 ISG, 222
- U**
- Upstream ORFs (uORF), 176
- V**
- Vectored vaccines, 256–257
- Viral and cellular mRNA translation, CoV.  
*See* mRNA translation, CoV
- Viral enzymes, 171–172
- Viral proteins, assembly and fusion  
 envelope protein  
 SARS-CoV, 10  
 structural features, 10–11  
 VLP, 9–10  
 membrane protein  
 appearance and characteristics,  
 7–8, 7*f*  
 endodomains, 6  
 MLONG-RNP interactions, 6  
 virus-like particles (VLP) assembly,  
 6–8
- nucleoprotein  
 conservation of, 9, 9*f*  
 C-terminal domain (CTD), 8–9  
 kinases, 8  
 N-terminal domain, 8–9
- spike protein  
 HR1 and HR2, 12–13  
 MERS-CoV, 12  
 S1 and S2 regions, 11–12  
 SARS-CoV, 12
- Viral UTRs, 177
- Virulence and vaccine development, CoV  
 ADEI and eosinophilia induction,  
 270–271  
 animal models  
 CRISPR-Cas9 system, 252–254  
 dipeptidyl peptidase-4  
 (DPP4), 252  
 HCoV-OC43, 251–252  
 hDPP4, 253  
 MERS-CoV, 252  
 SARS-CoV, 253  
 antigenic complexity, SARS- and  
 MERS-CoV, 250–251  
 antiviral selection  
 enzymatic activities, 273  
 inhibitors, vacuolar acidification,  
 273–274  
 p38 MAPK, 274  
 B- and T-cell responses, requirement of,  
 249–250  
 dendritic cells (DCs)  
 cytokines and chemokines, 273  
 immune cells, SARS-CoV and  
 MERS-CoV, 271, 272*t*  
 MERS-CoV interaction, 272  
 SARS-CoV, 272–273  
 virus replication, 271–272  
 epithelial cells, 271  
 genome structure and protein  
 composition, 248–249, 248*f*  
 human CoVs, 271  
 inactivated whole virus, 256  
 live-attenuated vaccines  
 engineer attenuated CoVs, 258  
 IFN sensitivity, 259–261  
 innate immunity modulators,  
 261–263, 261*f*



- MERS-CoV genes, 267–269
- SARS-CoV genes, 263–267
- virulence of, 258–259
- macrophages (MØ)
  - cytokines and chemokines, 273
  - immune cells, SARS-CoV
    - and MERS-CoV, 271, 272*t*
  - MERS-CoV interaction, 272
  - SARS-CoV, 272–273
    - virus replication, 271–272
- MERS-CoV, 247–248
  - pathogenesis, 246–247
  - prevalence, 246–247
  - SARS-CoV, 247–248
  - subunit vaccines, 254–256
  - vectored vaccines, 256–257